- GE Healthcare’s design for Deep Silicon detectors for a photon counting CT (PCCT) is engineered with the goal of achieving breakthroughs in both CT spatial and spectral resolution at the same time and increasing imaging performance across care areas
- Researchers at the University of Wisconsin–Madison will kick off research scanning human subjects with GE Healthcare’s latest generation PCCT prototype in December 2022, representing the first U.S.
For media inquiries, please contact:
Margaret Steinhafel
1 608 381 8829
[email protected]
business unit
- At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare proudly showcases cutting-edge solutions spanning the care continuum and enabling theranostics in prostate cancer
- This includes a new cyclotron Solid Target Platform which increases Gallium-68 production and access – a radioisotope used in molecular imaging for prostate cancer diagnosis, staging and monitoring
- The company also celebrates its 500th GE Healthcare cyclotron installation, a type of compact particle accelerator that produces radioisotopes fo
For media inquiries, please contact:
Margaret Steinhafel
GE Healthcare
+1 608 381 8829
[email protected]
business unit
- GE Healthcare, Medtronic receive FDA 510(k) clearance and CE Mark approval on the integration of advanced INVOS™ regional oximetry and Microstream™ capnography technologies on the CARESCAPE precision monitoring platform
- Helping providers improve patient outcomes and safety, Microstream™ capnography (CO2) technology captures evolving respiratory compromise while INVOS™ regional oximetry (rSO2) technology helps clinicians predict and prevent perioperative complications quicker than traditional peripheral measurement[i],[ii]<
For media inquiries, please contact:
Jennifer Purdue
Communications Director
GE Healthcare
+1-267-593-9735
[email protected] Tammy Hudson
Public Relations
Medtronic
+1-678-488-5337 Ryan Weispfenning
Investor Relations
Medtronic
+1-763-505-4626
business unit
- GE Healthcare introduces the industry’s first[i] computed tomography (CT) platform with built-in scalability and upgradability[ii]
- The new Revolution Apex platform offers the world’s fastest gantry speed: 0.23 seconds per rotation and 19.5 millisecond effective temporal resolution to freeze cardiac motion[iii]
- Altogether, the company’s CT platform enables healthcare facilities to keep up with the latest technology while minimizing technology obsolescence, optimizing clinical capabilities, and st
For media inquiries, please contact:
Margaret Steinhafel
+1 608 381 8829
[email protected]
America/Chicago
business unit
- Accommodates a greater variety of patients and provides a more complete look at every patient’s heart with enhanced scanning capabilities, including a 76 percent increase in field-of-view volume[i]
- Leverages GE Healthcare’s exclusive Alcyone technology, which can view cardiac anatomy and pathology with great clarity and speed
- Introduces several new automated features to help simplify workflows and expedite exams
CHICAGO – September 29, 2021 – GE Healthcare is
For media inquiries, please contact:
Margaret SteinhafelGE Healthcare
+1 608 381 8829
[email protected]
business unit
GE Healthcare invests in a unique approach to cutting-edge CT technology and acquires Prismatic Sensors AB, a leader in Deep Silicon detector technology for photon counting computed tomography (PCCT)
For media inquiries, please contact:
Margaret SteinhafelGE Healthcare
+1 608 381 8829
[email protected]
business unit
- Companies aim to develop jointly-branded clinical decision support software for faster, more accurate, more confident decision-making, enabling earlier diagnosis and individualized treatment
- Partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio
Chicago, USA Jan 8, 2018 - GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointl
business unit
GE Healthcare's priority is to provide safe products that help improve patient health. Recent publications indicate low levels of gadolinium are retained in the brain following repeated exposure to gadolinium-based contrast agents (GBCAs). We take very seriously any information concerning possible adverse events associated with our products.
business unit
GE releases 4Q’16 earnings.
Please click here to read the rest of the press release, in English.